Notice: This company has been marked as potentially delisted and may not be actively trading. ContraVir Pharmaceuticals (CTRV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CTRV vs. BPTH, SONN, SLRX, PHIO, GLMD, ALLR, DRMA, SXTP, PBLA, and SXTCShould you be buying ContraVir Pharmaceuticals stock or one of its competitors? The main competitors of ContraVir Pharmaceuticals include Bio-Path (BPTH), Sonnet BioTherapeutics (SONN), Salarius Pharmaceuticals (SLRX), Phio Pharmaceuticals (PHIO), Galmed Pharmaceuticals (GLMD), Allarity Therapeutics (ALLR), Dermata Therapeutics (DRMA), 60 Degrees Pharmaceuticals (SXTP), Panbela Therapeutics (PBLA), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "medical" sector. ContraVir Pharmaceuticals vs. Bio-Path Sonnet BioTherapeutics Salarius Pharmaceuticals Phio Pharmaceuticals Galmed Pharmaceuticals Allarity Therapeutics Dermata Therapeutics 60 Degrees Pharmaceuticals Panbela Therapeutics China SXT Pharmaceuticals Bio-Path (NASDAQ:BPTH) and ContraVir Pharmaceuticals (NASDAQ:CTRV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking. Do insiders & institutionals believe in BPTH or CTRV? 5.7% of Bio-Path shares are held by institutional investors. Comparatively, 1.1% of ContraVir Pharmaceuticals shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 1.6% of ContraVir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, BPTH or CTRV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/AContraVir PharmaceuticalsN/AN/A-$9.45MN/AN/A Do analysts rate BPTH or CTRV? Bio-Path currently has a consensus price target of $20.00, suggesting a potential upside of 2,403.13%. Given Bio-Path's stronger consensus rating and higher probable upside, analysts clearly believe Bio-Path is more favorable than ContraVir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ContraVir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer BPTH or CTRV? In the previous week, Bio-Path had 5 more articles in the media than ContraVir Pharmaceuticals. MarketBeat recorded 5 mentions for Bio-Path and 0 mentions for ContraVir Pharmaceuticals. Bio-Path's average media sentiment score of 0.93 beat ContraVir Pharmaceuticals' score of 0.00 indicating that Bio-Path is being referred to more favorably in the media. Company Overall Sentiment Bio-Path Positive ContraVir Pharmaceuticals Neutral Does the MarketBeat Community prefer BPTH or CTRV? Bio-Path received 63 more outperform votes than ContraVir Pharmaceuticals when rated by MarketBeat users. However, 74.49% of users gave ContraVir Pharmaceuticals an outperform vote while only 54.65% of users gave Bio-Path an outperform vote. CompanyUnderperformOutperformBio-PathOutperform Votes28254.65% Underperform Votes23445.35% ContraVir PharmaceuticalsOutperform Votes21974.49% Underperform Votes7525.51% Is BPTH or CTRV more profitable? Bio-Path's return on equity of -2,842.40% beat ContraVir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% ContraVir Pharmaceuticals N/A -4,810.77%-130.14% Which has more risk and volatility, BPTH or CTRV? Bio-Path has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, ContraVir Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. SummaryBio-Path beats ContraVir Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get ContraVir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTRV vs. The Competition Export to ExcelMetricContraVir PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$555,000.00$6.40B$5.02B$8.84BDividend YieldN/A8.11%5.28%4.07%P/E RatioN/A10.61111.4917.71Price / SalesN/A381.751,290.4594.95Price / CashN/A22.1633.9932.45Price / Book0.875.414.684.66Net Income-$9.45M$153.11M$116.66M$225.37M ContraVir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTRVContraVir PharmaceuticalsN/A$0.69+1.5%N/A-77.9%$555,000.00N/A0.0014BPTHBio-Path3.1611 of 5 stars$0.81-10.0%N/A-92.9%$2.07MN/A0.0010Analyst ForecastGap UpSONNSonnet BioTherapeutics1.666 of 5 stars$3.02+0.7%N/A+97.9%$2.06M$150,000.000.0012SLRXSalarius Pharmaceuticals0.1979 of 5 stars$1.34-2.9%N/A-75.0%$1.93M$1.84M-0.1620PHIOPhio Pharmaceuticals1.9812 of 5 stars$2.21-0.9%N/A-75.3%$1.90MN/A-0.208News CoverageGap UpGLMDGalmed Pharmaceuticals0.9519 of 5 stars$2.93-5.5%N/A-39.8%$1.89MN/A-0.1820Gap DownALLRAllarity Therapeutics0.3593 of 5 stars$1.32-6.4%N/A-99.6%$1.86MN/A0.005DRMADermata Therapeutics2.228 of 5 stars$1.12-5.9%N/A-89.7%$1.69MN/A-0.078SXTP60 Degrees Pharmaceuticals0.717 of 5 stars$0.90-5.3%N/A+25.1%$1.67M$250,000.00-0.093News CoverageGap DownPBLAPanbela Therapeutics1.2797 of 5 stars$0.33+6.6%N/A-97.3%$1.58MN/A0.007High Trading VolumeSXTCChina SXT Pharmaceuticals0.9871 of 5 stars$0.39-9.4%N/A-79.8%$1.57M$1.93M0.0090Positive NewsGap Down Related Companies and Tools Related Companies Bio-Path Competitors Sonnet BioTherapeutics Competitors Salarius Pharmaceuticals Competitors Phio Pharmaceuticals Competitors Galmed Pharmaceuticals Competitors Allarity Therapeutics Competitors Dermata Therapeutics Competitors 60 Degrees Pharmaceuticals Competitors Panbela Therapeutics Competitors China SXT Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTRV) was last updated on 11/19/2024 by MarketBeat.com Staff From Our PartnersTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraVir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTRV Stock Alerts